<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d506" origId="Isocarboxazid"><sentence id="DrugDDI.d506.s0" origId="s0" text="Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories)."><entity id="DrugDDI.d506.s0.e0" origId="s0.p0" charOffset="0-13" type="drug" text="Isocarboxazid"/><entity id="DrugDDI.d506.s0.e1" origId="s0.p7" charOffset="72-80" type="drug" text="Antabuse"/><entity id="DrugDDI.d506.s0.e2" origId="s0.p9" charOffset="82-92" type="drug" text="disulfiram"/><pair id="DrugDDI.d506.s0.p0" e1="DrugDDI.d506.s0.e0" e2="DrugDDI.d506.s0.e1" interaction="false"/><pair id="DrugDDI.d506.s0.p1" e1="DrugDDI.d506.s0.e0" e2="DrugDDI.d506.s0.e2" interaction="false"/><pair id="DrugDDI.d506.s0.p2" e1="DrugDDI.d506.s0.e1" e2="DrugDDI.d506.s0.e2" interaction="false"/></sentence><sentence id="DrugDDI.d506.s1" origId="s1" text="In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death."><entity id="DrugDDI.d506.s1.e0" origId="s1.p16" charOffset="63-76" type="drug" text="MAO inhibitor"/><entity id="DrugDDI.d506.s1.e1" origId="s1.p18" charOffset="82-92" type="drug" text="disulfiram"/><pair id="DrugDDI.d506.s1.p0" e1="DrugDDI.d506.s1.e0" e2="DrugDDI.d506.s1.e1" interaction="true"/></sentence><sentence id="DrugDDI.d506.s2" origId="s2" text="Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects."><entity id="DrugDDI.d506.s2.e0" origId="s2.p26" charOffset="19-32" type="drug" text="Isocarboxazid"/><entity id="DrugDDI.d506.s2.e1" origId="s2.p28" charOffset="43-62" type="drug" text="psychotropic agents"/><pair id="DrugDDI.d506.s2.p0" e1="DrugDDI.d506.s2.e0" e2="DrugDDI.d506.s2.e1" interaction="true"/></sentence><sentence id="DrugDDI.d506.s3" origId="s3" text="This is especially true in patients who may subject themselves to an overdosage of drugs."><entity id="DrugDDI.d506.s3.e0" origId="s3.p42" charOffset="83-88" type="drug" text="drugs"/></sentence><sentence id="DrugDDI.d506.s4" origId="s4" text="If combination therapy is needed, careful consideration should be given to the pharmacology of all agents to be used."/><sentence id="DrugDDI.d506.s5" origId="s5" text="The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid."><entity id="DrugDDI.d506.s5.e0" origId="s5.p55" charOffset="4-31" type="drug" text="monoamine oxidase inhibitor"/><entity id="DrugDDI.d506.s5.e1" origId="s5.p56" charOffset="44-57" type="drug" text="Isocarboxazid"/><entity id="DrugDDI.d506.s5.e2" origId="s5.p61" charOffset="124-128" type="drug" text="drug"/><entity id="DrugDDI.d506.s5.e3" origId="s5.p69" charOffset="176-180" type="drug" text="drug"/><entity id="DrugDDI.d506.s5.e4" origId="s5.p73" charOffset="205-218" type="drug" text="Isocarboxazid"/><pair id="DrugDDI.d506.s5.p0" e1="DrugDDI.d506.s5.e0" e2="DrugDDI.d506.s5.e1" interaction="false"/><pair id="DrugDDI.d506.s5.p1" e1="DrugDDI.d506.s5.e0" e2="DrugDDI.d506.s5.e2" interaction="false"/><pair id="DrugDDI.d506.s5.p2" e1="DrugDDI.d506.s5.e0" e2="DrugDDI.d506.s5.e3" interaction="false"/><pair id="DrugDDI.d506.s5.p3" e1="DrugDDI.d506.s5.e0" e2="DrugDDI.d506.s5.e4" interaction="false"/><pair id="DrugDDI.d506.s5.p4" e1="DrugDDI.d506.s5.e1" e2="DrugDDI.d506.s5.e2" interaction="false"/><pair id="DrugDDI.d506.s5.p5" e1="DrugDDI.d506.s5.e1" e2="DrugDDI.d506.s5.e3" interaction="false"/><pair id="DrugDDI.d506.s5.p6" e1="DrugDDI.d506.s5.e1" e2="DrugDDI.d506.s5.e4" interaction="false"/><pair id="DrugDDI.d506.s5.p7" e1="DrugDDI.d506.s5.e2" e2="DrugDDI.d506.s5.e3" interaction="false"/><pair id="DrugDDI.d506.s5.p8" e1="DrugDDI.d506.s5.e2" e2="DrugDDI.d506.s5.e4" interaction="false"/><pair id="DrugDDI.d506.s5.p9" e1="DrugDDI.d506.s5.e3" e2="DrugDDI.d506.s5.e4" interaction="false"/></sentence><sentence id="DrugDDI.d506.s6" origId="s6" text="To avoid potentiation, the physician wishing to terminate treatment with Isocarboxazid and begin therapy with another agent should allow for an interval of 10 days."><entity id="DrugDDI.d506.s6.e0" origId="s6.p80" charOffset="73-86" type="drug" text="Isocarboxazid"/></sentence></document>